Format

Send to:

Choose Destination

ERX2218758: Illumina MiSeq sequencing
1 ILLUMINA (Illumina MiSeq) run: 2.5M spots, 622.5M bases, 181.2Mb downloads

Submitted by: MD ANDERSON CANCER CENTER
Study: Gut microbiome impacts response to PD-1 immunotherapy in melanoma patients
show Abstracthide Abstract
Pre-clinical mouse models have suggested that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy, however this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing PD-1 blockade immunotherapy (n=112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders (R) versus non-responders (NR). Analysis of patient fecal microbiome samples (n=43, 30R, 13NR) showed significantly higher alpha diversity (p<0.01) and relative abundance of Ruminococcaceae bacteria (p<0.01) in R. Metagenomic studies revealed functional differences in gut bacteria in R including enrichment of anabolic pathways. Immune profiling found enhanced systemic and anti-tumor immunity in responding patients with a favorable gut microbiome, as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for treatment with immune checkpoint blockade in melanoma.
Sample: Wargo.109865
SAMEA104335966 • ERS1960944 • All experiments • All runs
Organism: Homo sapiens
Library:
Name: unspecified
Instrument: Illumina MiSeq
Strategy: AMPLICON
Source: METAGENOMIC
Selection: PCR
Layout: SINGLE
Runs: 1 run, 2.5M spots, 622.5M bases, 181.2Mb
Run# of Spots# of BasesSizePublished
ERR21622252,450,118622.5M181.2Mb2017-11-07

ID:
4703970

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center